

Subject Index

- Abscondance, 422
Abstinence
 abstainers, 157
 brain atrophy in abstinent alcoholics, 75–76, 89–95
 cocaine, 313–320
 non-abstinent and abstinent outcomes, 279–287
 opiate addicts, 169
 programs/clinics, 231–235, 306–309
Abstinence violation effect, 307–308
Acquired immune deficiency syndrome (AIDS), 13, 403, 428, 474, 503
Addiction Severity Index (ASI), 326, 327–328, 330, 331
Addictions treatment
 civil commitment approaches, 417–430
 coercion in, 403–451
 growth areas in, 297–310
 pharmacological approaches in, 302–304
Adolescents
 alcohol and marijuana prevention, 460–461
 communitywide prevention efforts, 465–466
 cross-national studies of drinking, 2–5
 drug use, 37–50, 156–157
 early substance abuse prevention programs, 456–457
 Life Skills Training (LST) program, 461–463, 476–477
 mass media interventions, 463–465
 Midwestern Prevention Project (MPP), 489–501
 policy-level interventions for adolescent drug use, 466–467
 preventing adolescent drug abuse, 453–461, 473–485, 489–507
 primary treatment programs, 227, 229, 232
 smoking prevention, 459–460
 social influences model of substance use prevention, 457–459
 youth treatment services, 250, 252, 260–267, 275–276, 277–278
Adoption studies, alcoholism, 207–208
Adult Children of Alcoholics, 361
Adverse Consequences Index, 369
African-Americans. *See Blacks*
Alcohol
 classification of alcohol problems, 116–117, 147–148
 consumption and neuroimaging changes, 75–76
 controlled drinking, 279–287
 drinking behavior of rats, 193–202
 first pass metabolism of ethanol, 81–88
 metabolizing genes studies, 210–211
 treatment programs, 231–235, 333–340
 use of cocaine and, 17–23
Alcohol abuse, neuropsychological syndromes associated with, 61–76
Alcohol dehydrogenase (ADH), 210–211, 219
Alcohol dependence syndrome, 110, 111–113, 145
Alcohol withdrawal, 75–76, 89–95, 166–167
Alcoholic dementia (AD), 61, 65
Alcoholics
 brain atrophy in abstinent, 75–76, 89–95
 children of, 156, 177–191
 choice of drinking goals in alcoholic treatment program, 333–339
 communication skills training for, 367–374
 matching studies, 309–310
 neuroimaging of, 62–64, 71–76
 neuropsychological impairment in, 62, 64–71
 self-help groups for, 345–346, 349–350
 sons of male alcoholics (SOMAs), 160, 162–164, 165
 subtypes of, 67, 117–120
 subtyping male, 125–134
 treatment matching, 323–331
 Type I and Type II, 120, 208, 219, 308, 309, 335, 336–337, 339
Alcoholics Anonymous, 226, 305, 345–383, 397–399, 401–402, 407, 410, 411, 412
12-step program and problems other than alcohol, 358–363
12-step treatment and development as social movement, 354–358
 as a belief and interaction system, 350–354

- Alcoholics Anonymous (*continued*)**
 as a self-help movement, 346–350
 communication skills training, 367–374
 organizational principles, 348–349
 and other self-help groups, 349–350
 spirituality and recovery, 375–383
 structure of, 347–348
- Alcoholism**
 aging and, 34, 64
 and anxiety disorders, 165
 association and linkage studies, 209
 comorbidity, 31, 70, 204
 cross-national studies of, 1–13
 definitions of controlled drinking, 279–287
 disease concept, 292, 351, 404
 ethnicity and, 66
 family history of, 66–67, 125–134, 205–208
 gender and, 64, 66
 genetic control of, 154–155
 genetic epidemiology of, 203–212
 laboratory testing, 240–241
 literature, 361, 362
 multigenerational family histories (MFH) of, 163, 164, 165
 in North America and Asia, 25–35
 and schizophrenia, 34
 socioeconomic status, 66
 sociopathic traits, 309–310, 324
 treatment programs, 333–340
 vulnerability studies, 209–210
- Aldehyde dehydrogenase (ALDH)**, 210–211, 219
- American Drug and Alcohol Survey (ADAS)**, 38–39, 42, 48, 453, 454, 455
- Amethyst project**, 298, 299
- Anti-social personality disorder**
 alcoholism comorbidity, 31, 70
 Axis I and II subtypes, 118–119
 children with ERP reactions and, 191
 depression and ASP subtypes, 149–150
 familial alcoholism and, 67, 130–131
 lifetime prevalence rates, 159–160
 sensation-seekers and, 159
- Anxiety Sensitivity Index**, 165
- Anxiety system**, 161–167
- ASI Psychiatric Severity**, 326, 327–328, 330, 331
- Asian-Americans**, youth drug use, 39, 44, 455–456
- Attention Deficit/Hyperactivity Disorder (ADHD)**, 68
- Axis I/Axis II subtypes**, 118–120
- Behavioral pathology**, 109–151
 diagnostic classification system, 109–121
 substance dependence syndrome and opiate users, 137–143
 subtyping male alcoholics, 125–134
- Blacks**
 drug offenders, 437, 440–442
 lifetime prevalence rates, 34
 use of alcohol and cocaine, 19–23
 youth drug use, 38, 39, 44, 45, 46, 455–456
- Blood alcohol content (BAC)**, 38
- Blood alcohol levels**, in women, 81–88
- Brain atrophy**
 in abstinent alcoholics, 89–95
 cerebellar atrophy in alcoholics, 74, 75–76
 frontal lobe atrophy in KS patients, 72
- Brainwashing**, 387
- Bulimia nervosa**, 304
- California Civil Addicts Program (CAP)**, 405, 408–409
 civil commitment approaches, 417–430
- California Psychological Inventory Socialization Scale (CPT-So)**, 326, 328, 330
- California Society of Addiction Medicine**, 227
- Charismatic groups**, 385–388
- Children**
 of alcoholics, 156–157, 177–191
 with Attention Deficit/Hyperactivity Disorder (ADHD), 68
 ERP reactions of, 163
- Children of God**, 386
- Civil commitment and narcotics addiction**, 417–430
- Cocaine**, 72–73, 156, 259, 304, 305, 306
 abstinence, 313–320
 abuse on dopamine receptors, 72–73, 97–103
 and amphetamine users, 160
 use of alcohol and, 11, 17–23
 withdrawal, 115, 160–161
- Cocaine Abuse History and Inventory**, 316
- Cocaine Anonymous**, 359, 401
- Cocaine Use Inventory and Craving Scale**, 316
- Coercion**
 forms of, 404–406, 408
 legal, 427–429
 studies and treatments in, 409–411
- Coercion in addictions treatment**, 403–451
 civil commitment approaches, 417–430
 sentencing of drug offenders, 431–443
- Cognitive performance**, and brain atrophy, 89–95

- Cognitive-behavioral drug abuse prevention, 475-485
 Life Skills Training (LST) Program, 476-477
- Collaborative Alcohol-Related Longitudinal Project, 3-4, 10-11, 13
- Communications skills training, 367-374
- Comorbidity
 alcoholism, 31, 70, 204
 dual diagnosis rates and subtypes of, 113-114, 117-120
 psychiatric, 125-134
- Composite International Diagnostic Interview (CIDI), 54
- Comprehensive Drug Reform Act (NJ), 449-450
- Computer assisted tomographic (CAT) scanning, 62-63, 71-73, 90-94, 105-106
- Controlled drinking, 279-287. *See also Abstinence*
- Coping skills training, 323-331
- Cuban-Americans, youth drug use, 46
- Cults and zealous self-help movements, 385-396
- Cultural specificity, 1-13
- D, L-5-Hydroxytryptophan (5-HT), 194-197, 199-201
- Daytop Village, 392
- Dependence Symptoms Scale, 369
- Depression
 alcoholism comorbidity, 31, 71, 204
 anxiety and, 165
 and ASP subtypes, 149-150
 female, 150, 168
 opiate addiction and, 168-169
- Desipramine hydrochloride, 313-320
- Diagnostic and Statistical Manual of Mental Disorders.* *See DSM-III-R*
- Diagnostic classification system, 109-121
 Axis I and II subtypes, 118-120
 Type I and Type II alcoholics, 120
- Diagnostic Interview Schedule (DIS), 7, 54, 114-115, 178, 234, 238
 population surveys using the, 25-35
- Digit Symbol subtest, 326
- Digital blood volume amplitude (DBVA), 163
- Dihydroxyphenylacetic acid (DOPAC), 197
- Diseases
 alcoholism disease concept, 292, 351, 404
 liver, 69, 71, 82
 Marchiafava-Bignami disease (MB), 73
 systemic, 69
- Disulfiram, 303, 304, 335
- Divine Light Mission, 386, 387, 389
- Dopamine
 receptors, 72-73, 97-103, 157, 158-159, 218-219
 serotonin and GABA, 193-202
- Drinking Reasonably and Moderately with Self-control (DRAMS), 301
- Drug abuse screening test (DAST), 241, 242, 290
- Drug abuse treatment services. *See Treatment programs, alcohol and drug abuse*
- Drug Abuse Warning Network (DAWN), 18
- Drug addiction etiology, 153-170
- Drug and alcohol survey, youth, 39
- Drug offenders, sentencing of, 431-443
- Drug Taking Evaluation Scale (DTES), 335, 337
- Drugs, 40, 42, 43, 45, 47
 acamprosate, 304
 alcohol, 41, 157, 158
 amphetamines, 158, 160
 antidepressants, 292, 304
 anxiolytic drugs, 161-167
 barbituates, 157, 165, 167
 benzodiazepines, 157, 165, 166, 167, 307
 desipramine hydrochloride, 313-320
 deterrent, 303-304
 disulfiram, 303, 304, 335
 experimentation with, 155-157
 gateway, 42, 490
 heroin, 42
 inhalants, 42
 lithium carbonate, 292, 314-319
 marijuana, 41, 42, 156
 methadone maintenance and civil commitment, 424-426
 morphine, 169
 naltrexone, 303-304
 opiates, 137-143, 157, 167-169, 303, 306, 307
 PCP, 42
 polydrug abusers, 223, 225, 231, 236
 polysubstance abuse, 72-73, 205
 Schedule I drug, 432-433
 serotonin uptake inhibitors, 304
 stimulants, 41, 158, 160-161
 tobacco, 41
- DSM-II, 111
- DSM-III, ASP criteria, 329
- DSM-III-R
 alcoholic dementia and Korsakoff's Syndrome criteria, 61
 alcoholism criteria, 26-28, 32-33, 58, 127, 178, 204, 306, 324

- DSM-III-R (continued)**
- substance dependence syndrome criteria, 137-138, 140, 143
 - substance use disorders criteria, 53, 54, 58, 110, 111-112, 113, 114, 115, 116, 117, 119
- DSM-IV**, 55, 109, 115, 119, 143, 153
- Dual diagnosis subtypes**, 113-114, 117-120
- DWI offenders**, 410, 412, 413
- Dysthymic disorder**, 31
- Early intervention**, 297-302
- Emergent treatment concepts**, 297-344
- abstinence programs/clinics, 306-309
 - choice of drinking goals in alcoholic treatment program, 333-339
 - cocaine abstinence, 313-320
 - intervention, 297-302
 - matching studies, 309-310
 - pharmacological approaches, 302-304
 - treatment matching, 323-331
- Emotions Anonymous**, 358
- Employee-assisted programs (EAP)**, 133, 238, 404-405, 410, 445-447
- Encephalopathy**, 61. *See also Wernicke-Korsakoff Syndrome*
- Enzymes**
- alcohol dehydrogenase (ADH), 210-211, 219
 - aldehyde dehydrogenase (ALDH), 210-211, 219
 - gamma-glutamyl transferase (GGT), 69
- Epidemiologic Catchment Area (ECA)**, sampling bias study, 110, 113-114, 145, 146
- Epidemiologic Catchment Area (ECA) study**, 54, 153, 204
- St. Louis survey data, 27, 28, 32, 33, 34
- Epidemiology**, 1-59
- cross-national studies of drinking, 1-13
 - lifetime prevalence rates, 28-30, 32-34, 40, 41, 43, 45, 47
 - national and local surveys on adolescent drug use, 37-50
 - population surveys, alcoholism, 25-35
 - use of alcohol and cocaine survey, 17-23
- Etiology**, 153-221
- children of alcoholics, 177-191
 - drug addiction, 153-170
 - genetic epidemiology of alcoholism, 203-212
 - serotonin, dopamine and GABA, 193-201
- Event-related potential (ERP)**, 162
- in children of alcoholics, 177-191
- Familial transmission of alcoholism**, 205-208
- adoption studies, 207-208
 - twin studies, 206-207
- Family history**
- alcoholism, 66-67
 - multigenerational family histories (MFH), 163, 164, 165
 - subtyping male alcoholics using, 125-134
- Family-history-negative (FHN)**, 126, 130, 131
- Family-history-positive (FHP)**, 126, 130, 131, 134, 155, 163
- Federal Public Health Service (USPHS)**, 417
- Fetal alcohol syndrome (FAS)**, 66, 67
- Flushing, facial**, 6, 33, 66
- Four-Word Short Term Memory Test**, 326
- Functional imaging**, 73-74
- GABA system**, 165-167
- serotonin, dopamine and, 193-202
- Gamblers Anonymous**, 358
- Gamma-glutamyl transferase (GGT)**, 69
- Gastric alcohol dehydrogenase**, 81-88
- Gateway drugs**, 42, 490
- Georgia**, sentencing of drug offenders in, 431-443
- Global Assessment Scale**, 316
- Hare Krishna**, 386
- Harvard Alcohol Project**, 464
- Hazelden model clinic**, 305, 306
- Head injuries**, 69-70
- Healthy cities movement**, 503-504
- Healthy People**, 490
- High intensity drinking**, 233-235
- Hispanic-Americans**, 6
- use of alcohol and cocaine, 19-23
 - youth drug use, 44, 46, 455
- Hollingshead's Four Factor Index of Social Status**, 179
- Homovanillic acid (HVA)**, 197-198
- Hudson Generalized Contentment Scale (GCS)**, 376-382
- 5-Hydroxyindoleacetic acid (5-HIAA)**, 194-196
- Impaired Physicians Program of Georgia**, 391
- Inpatient treatment**, 304-306
- Institutional treatment and self-help groups**, 391-393
- Interactional group therapy**, 323-331
- Intercranial self-stimulation (ICS)**, 158
- International Classification of Diseases and Related Health Problems (ICD-10)**, 53, 54, 55, 109-110

- Intervention, definition, 297-302
 Iowa Stages Index, 411
- Japanese-Americans, drinking patterns, 6, 7, 10
 Jews and Israelis, alcoholism, 7
 Jourard Self-Disclosure Questionnaire, 372
- Korsakoff's Syndrome (KS), 61-62, 65, 66, 71, 72, 73, 74, 76, 105-106. *See also* Wernicke-Korsakoff Syndrome
- Laboratory testing, alcoholism, 240-241
 Last-chance agreements, 446-447
 Lay treatment community, 345-402
 AA communication skills training, 367-374
 AA spirituality and recovery, 375-383
 Alcoholics Anonymous, 345-363
 cults and zealous self-help movements, 385-394
 Life Events Scale (LE), 376-379, 383
 Life Skills Training (LST) program, 461-463, 476-477
 Lifetime prevalence rates
 alcohol abuse, 28-30, 32-34
 ASP, 159-160
 drug use, adolescent, 40, 41, 43, 45-47
 psychiatric syndromes of male alcoholics, 128-134
 substance use disorders, 113-114
 Links, 349-350
 Lithium carbonate, 292, 314-319
 Liver dysfunction, 69, 71, 82
 Longitudinal, Expert diagnoses based on All available Data (LEAD), 116
- MacAndrews Alcoholism scale, 118
 Magnetic resonance imaging (MRI), 62-63, 71, 73, 105-106
 Managed care, 304
 Marchiafava-Bignami disease (MB), 73
 Marijuana, 41, 42, 156
 Mass media interventions, 463-465
 Matching studies, 309-310
 Maternal drinking, 155
 Maudsley study, 280-281
 Mental illness, zealous self-help movements and, 389-390
 Methadone maintenance and civil commitment, 424-426
 Mexican-Americans
 drinking patterns, 5, 6-7, 10
 youth drug use, 39, 44, 45, 46-47
 Michigan Alcoholism Screening Test, 411
- Midwestern Prevention Project (MPP), 466, 489-501
 Minneapolis Plan, 305
 Minnesota Heart Health Program, 465
 Minnesota Multiphasic Personality Inventory (MMPI), 118, 238, 253, 268
 Minnesota Smoking Prevention Program (MSPP), 459
 Monitoring the Future project, 455
 Monoamine oxidase (MAO), 219
 Mothers Against Drunk Driving (MADD), 403, 467
- Naltrexone, 303-304
 Narcotics addiction, civil commitment approaches in, 417-430
 Narcotics Addiction Rehabilitation Act (NARA), 426, 427
 Narcotics Anonymous, 358, 401
 National Adolescent Student Health Survey, 40, 41-42
 National Alliance for the Mentally Ill, 393
 National Cancer Institute (NCI), 459
 National Household Survey on Drug Abuse, 18, 40-41
 National Institute on Alcohol Abuse and Alcoholism (NIAAA), 237-238, 402
 National Institute on Drug Abuse, 37-38, 44
 National Institutes on Health, 224
 National Senior Survey, 40-41
 Native-Americans, youth drug use, 39, 44, 45, 50, 455
 Neuropsychological syndromes, alcohol abuse, 61-76
 Neuropeptide cholecystokinin (CCK), 159
 New York State Narcotic Addiction Control Commission (NACC), 405
 North Kelia Youth Project, 465
- Obsessive-compulsive disorders, 304
 One-parameter/two-parameter models, 139-140
 Ontario Working Group to Develop a Directory of Outcome Measures, 237
 Opiate abuse, substance dependence syndrome, 137-143
 Opiate, addiction, 303, 306, 307
 and depression, 168-169
 naltrexone, 303-304
 Opiates and pain/loss/disappointment system, 167-169
 Out-patient alcoholic treatment program, 333-340
 Overeaters Anonymous, 358

- Pain/loss/disappointment system, 167–169
Pathophysiology, 61–108
 brain atrophy in abstinent alcoholics, 89–95
 cocaine abuse on postsynaptic dopamine receptors, 97–103
 high blood alcohol levels in women, 81–88
 neuropsychological syndromes, 61–76
Peer-led programs, 458–459
Pellagra, 69
PFI Social Behavior, 327, 328
Pharmacological approaches, 302–304
Phoenix House, 392
Planimeter measurement, 63, 72
Polydrug abusers, 223, 225, 231, 236
Polysubstance abuse, 72–73, 205
Positron emission tomography (PET), 63, 72, 74, 98–102, 105–106
Prevention, 453–507
 preventing adolescent drug abuse, 453–468, 473–485, 489–501
Primary and secondary disorders, 115–116
Problem drinking scale (PDS), 283
Program evaluation and treatment outcome, 223–295
 adult and youth treatment services, 249–278
 monitoring treatment outcomes, 223–246
 non-abstinent and abstinent outcomes, 279–287
Project DARE, 460–461
Project MATCH, 238, 290
Project Northland, 466
Project SMART, 460
Psychiatric Diagnostic Interview (PDI), 127
Psychiatric disorder, family history of, 125–134
Psychiatrically disabled, self-help for the, 393
Psychoactive Substance Dependence and Abuse (PSDA) syndrome, 137–143
Psychomotor system, 157–161
Psychosocial Functioning Inventory, 238
Psychotherapy, approaches to, 324

Radiofrequency (RF) energy, 62–63
Rand Drinking Symptoms Checklist, 411
Rand report, 282–283
Rasch model, 139
Rats, drinking behavior, 193–202
Recovery, Inc., 389–390
Regional cerebral blood flow (rCBF), 63, 73–74
Religion, spirituality and recovery, 375–383
Renard Diagnostic Interview, 178
Research Diagnostic Criteria (RDC), 114, 119, 316, 319

Salience, measure, 141–143
Saving Lives Program (MA), 467
Schedule for Affective Disorders and Schizophrenia (SADS), 111, 114, 316
Schizophrenia, 34
Self-help groups for alcoholics, 345–346, 349–350
Self-help movements, cults and zealous, 385–394
Sensation-seekers, 155, 159
Serotonin
 dopamine and GABA, 193–201
 GABA system and, 166
 uptake inhibitors, 304
Serum glutamic oxaloacetic transaminase (SGOT), 241
Sex differences, 64, 66
Short Michigan Alcoholism Screening Test (SMAST), 411
Single photon emission tomography (SPECT), 63, 105–106
A Skeptic's Guide to the Twelve Steps, 362
Sober Times, 363
Social drinking, concept of, 281–282
Social movements, 354–355
Sons of male alcoholics (SOMAs), 160, 162–164, 165
Soteria House, 392
Spanish-Americans, youth drug use, 45, 46
Spirituality Self-Assessment Scale (SSAS), 355, 362, 376–381
Stages of Change model, 411, 413
Stimulant abusers, 41, 158, 160–161
 opiates as psychomotor stimulants, 167, 169
Stress-response dampening, 164
Structured Clinical Interview for DSM-III-R (SCID), 114, 115, 139, 140–142
Substance abuse treatment, coercion in, 403–415
Substance dependence syndrome, and opiate users, 137–143
Substance use disorders, 109–121
Substance use prevention, adolescent, 457–459, 473–485
 alcohol and marijuana prevention, 460–461
 communitywide prevention efforts, 465–466
 early, 456–457
Life Skills Training, 461–463, 476–477
 mass media interventions, 463–465
Midwestern Prevention Project (MPP), 489–501
 policy-level interventions, 466–467
 smoking prevention, 459–460

- Superconducting quantum interference devices (SQUIDS), 106
- Systemic diseases, 69
- Teenager's Self Test: Cigarette Smoking*, 479
- Testosterone, 159
- "The War on Drugs," 403
- Time-Line Follow-Back assessment, 326
- Trail Making Test, 326
- Treatment, usage of term, 397-398
- Treatment Alternatives to Street Crime, 412
- 1988 Treatment Outcome Study (TOS), 249-267
- Treatment programs, alcohol and drug abuse abstinence programs/clinics, 231-235, 306-309
- adult and youth treatment services, 249-278
- inpatient treatment, 304-306
- monitoring treatment outcomes, 223-246
- non-abstinent and abstinent outcomes, 279-287
- out-patient alcoholic treatment program, 333-340
- Triaging, 228
- Tricyclic antidepressants, 304
- Tumor-node-metastasis (TNM) system, 116, 148
- Twelve-Step groups and programs, 358-363, 390-391. *See also* Alcoholics Anonymous
- Twin studies, alcoholism, 206-207
- Type I and Type II alcoholism, 120, 208, 219, 308, 309, 335, 336-337, 339
- Unification Church ("Moonies"), 385, 386, 387, 388
- U.S. Alcohol, Drug Abuse and Mental Health Administration (ADAMHA), 54
- Urban bias, 2, 3
- Ventricular brain ratios (VBRs), 63, 72
- War on drugs, U.S., 431-433
- Wechsler Adult Intelligence Scale-Revised (WAIS-R), 61, 326, 330
- Wernicke-Korsakoff Syndrome, 61, 69, 74, 94, 95
- White-Americans
- use of alcohol and cocaine, 19-22
 - youth drug use, 38, 39, 44, 45, 46, 455-456
- WHO Collaborative Study, 461, 505, 506
- Wisconsin Card Sorting test, 326, 329
- Women
- AA members, 350
 - age-of-onset of alcoholism, 204
 - alcoholics, 64, 76
 - anxiety-sensitive, 165
 - female depression, 150, 168
 - fetal alcohol syndrome (FAS), 66, 67
 - high blood alcohol levels in, 81-88
 - lifetime prevalence of alcoholism, 30-31, 33, 34
 - maternal drinking, 155
 - use of alcohol and cocaine, 19
- World Health Organization (WHO), 54, 138, 141
- Youth Risk Behavior Survey, 455
- Zealous self-help movements and cults, 385-396

